MetaCap

SELLAS Life Sciences Group (SLS) vs Telix Pharmaceuticals (TLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SELLAS Life Sciences Group (SLS) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 792.8% versus a loss of 6.1%. Telix Pharmaceuticals is the larger company by market cap ($2.84 billion vs $2.78 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

SLS+792.81%TLX-6.06%
+1211%+562%-87%
Nov 21, 20251 yearNov 20, 2026
SLS+934.85%TLX-43.64%
+1128%+508%-112%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

SLS versus TLX key metrics
MetricSLSTLX
Share price$13.66$8.37
Market cap$2.78B$2.84B
1-day change-8.08%-3.90%
YTD return+262.33%+11.75%
1-year return+792.81%-6.06%
5-year return+94.03%—
P/E ratio (TTM)—83.70
EPS (TTM)$-0.20$0.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$803.79M
Revenue growth (YoY)—+55.61%
Net income (latest FY)$-26.86M$-7.13M
Gross margin—53.05%
Operating margin—3.70%
Net margin—-0.89%
52-week high$24.89$13.11
52-week low$1.39$6.28
Distance from 52-week high-45.12%-36.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+137.92%+134.89%
Average volume9.64M356.74K
Shares outstanding203.86M339.78M
Employees131,120
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLS has outperformed TLX by 798.9 percentage points over the past year.

About SELLAS Life Sciences Group

SLS stock →

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Telix Pharmaceuticals

TLX stock →

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees

SLS vs TLX FAQ

Which is bigger, SELLAS Life Sciences Group or Telix Pharmaceuticals?

Telix Pharmaceuticals (TLX) is larger, with a market capitalization of $2.84B compared with $2.78B for SELLAS Life Sciences Group (SLS).

Which stock has performed better over the past year, SLS or TLX?

SLS returned +792.81% over the past 12 months, compared with -6.06% for TLX (price return, excluding dividends). Past performance does not predict future results.

Are SELLAS Life Sciences Group and Telix Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons